News and Announcements
Actinogen has US Patent Granted and Further Extends Xanamem Protection
- Published July 21, 2016 3:26PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
20th July 2016, ASX Announcement
- United States Patent granted for use of Xanamem™ in Alzheimer’s dementia and other diseases.
- Xanamem™’s long patent life now further extended to 2031 in the US.
- Comprehensive protection over Xanamem™ now received for most major markets.
Actinogen Medical Limited (Actinogen Medical, ASX: ACW), is pleased to announce it has received official notification to grant from the United States Patent Office for the most comprehensive patent for Xanamem. This patent further extends the comprehensive cover for Xanamem through to 2031.
The patent ( US 9,365,654 B2) protects use of Xanamem™ for use in Alzheimer’s dementia and other relate diseases associated with the inhibition of the 11-beta-hydroxysteroid dehydrogenase (11β-HSD1) enzyme. Importantly this patent cover through to 2031 comes on top of previous approvals in most other major markets, including all European countries and the UK, Australia, Japan and China.
To view the full announcement, please click on the button below.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
